【two mile landing early bird menu】Roche Gets Emergency FDA Approval For Covid-19 Antibody Test, Starts Shipping
Switzerland’s Roche Holding AG (
RHHBY
) announced on Sunday that its antibody test,two mile landing early bird menu which seeks to determine if an individual has been infected with the coronavirus, has received emergency approval by the U.S. Food and Drug Administration (FDA).
“We are now able to deliver a high-quality antibody test in high quantities, so we can support healthcare systems around the world with an important tool to better manage the COVID-19 health crisis,” said Severin Schwan, CEO of the Roche Group. ”I am in particular pleased about the high specificity and sensitivity of our test, which is crucial to support health care systems around the world with a reliable tool to better manage the COVID-19 health crisis.”
The Swiss drugmaker said it has already started shipping the antibody tests to leading laboratories around the world and will ramp up production capacity to provide “high double-digit millions” of tests in May to healthcare systems in countries accepting the European CE regulatory mark as well as the U.S.
The antibody test, which has a specificity greater than 99.8% and 100% sensitivity aims to help assess patients’ immune response to the virus, the drugmaker said.
HSBC analyst
Stephen McGarry
on Thursday raised the stock to Hold from Sell, saying that the drugmaker represents one of the more secure bets within the pharmaceutical sector.
McGarry noted that compared to other industries, sales and cash flows of the pharmaceutical industry in the Covid-19 realm are well protected.
The two Wall Street analysts covering the stock in the past three months are split between a Buy and a Hold rating adding up to a Moderate Buy consensus rating. The $48 average
price target
indicates that they see 12% upside potential in the shares in the next 12 months.
Related News:
Gilead’s Remdesivir Receives Emergency FDA Approval; Here’s What This Five-Star Analyst Has To Say
Gilead Down 5% As Q1 Earnings Spark Street Downgrades
Vaxart Shows Strong Progress in Its COVID-19 Program; 5-Star Analyst Boosts Price Target
View comments
相关文章
Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
Agios Pharmaceuticals, Inc.(AGIO) announced that the phase III ACTIVATE study, which evaluated its f2024-09-29Evaluating New Times Energy Corporation Limited’s (HKG:166) Investments In Its Business
Want to help shape the future of investing tools? Participate in ashort research studyand receive a2024-09-29BRIEF-China National Nuclear Power Says 2018 Power Generation Up 16.97 Percent Y/Y
Jan 2 (Reuters) - China National Nuclear Power Co Ltd :* SAYS 2018 POWER GENERATION UP 16.97 PERCENT2024-09-29Ethics Forum: Questions and Answers on Professional Responsibility
Samuel C. Stretton.Samuel C. Stretton.Lawyers cannot share fees with nonlawyers.A nonlawyer who is a2024-09-29Is VirnetX Holding Corporation (VHC) A Good Stock To Buy?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million e2024-09-2915 Biggest Steel Companies In The World
In this article we are going to list the15 biggest steel companies in the world. Click to skip ahead2024-09-29
最新评论